Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Syra Health Delivers Third Quarter 2024 Financial Results

SYRA

Achieved Net Revenue of $2.3 million, ~42% Growth Over the Prior Year Quarter

Gross Margins Increased Following Shift in Operational Strategy

Net Loss Narrowed to $417,535 ($0.06 per share), a Significant Improvement from the $1.39 million ($0.21 per share) Net Loss in Q2 of 2024

Aiming to Attain Profitability in 2025 through Targeted Revenue Growth and Cost-Efficiency Measures

Conference call will be held today, Tuesday, October 29th at 9:00 AM ET

CARMEL, Ind., Oct. 29, 2024 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA), ("Syra Health" or the "Company") a healthcare technology company driving better health through impactful, innovative solutions, announced today its financial results for the third quarter ended September 30, 2024.

Syra Health - A catalyst for improving health outcomes. (PRNewsfoto/Syra Health)

Financial Highlights – 2024 Fiscal Third Quarter

Year over Year – Q3 2024 vs. Q3 2023

  • Achieved Net Revenue of $2.3 million, ~42% growth compared to 3Q23.
  • Population Health continues to grow, driven by demand for our public health services with revenues up 36%, alongside strong contributions from legacy Healthcare Workforce services with revenues up 54% compared to 3Q23.
  • Gross profit margin was 30% in 3Q24, compared to 35% in 3Q23, reflecting a milestone-based revenue recognition from our first digital health product in 3Q23.
  • Cash balance of $2.7 million at end of 3Q24 with no long-term debt, providing an estimated capital runway of approximately two years.

Third Quarter 2024 vs. Second Quarter 2024

  • Total Revenue increased 14.4% compared to 2Q24.
  • Gross profit margin was 29.7% in 3Q24 compared to 17.8% in 2Q24, an increase of 1190 bps.
  • Net loss for 3Q24 showed a 69% reduction compared to 2Q24 demonstrating a consistent move toward profitability.
  • Net loss per share decreased to $(0.06) in 3Q24 from $(0.21) in 2Q24.
  • Total operating expenses in 3Q24 decreased 37% compared to 2Q24.

Recent Operational Highlights

  • Successfully implemented cost-saving initiatives for sustainable impact
    • Achieved a 37% overall reduction in operating expenses in 3Q24 compared to 2Q24.
    • SG&A expenses decreased by 37% in 3Q24 compared to 2Q24.
    • Realized a 30% decrease in salaries and benefits costs in 3Q24 compared to 2Q24.
  • Launched Syrenity, a mental health app built on clinically proven practices and ethical, compliant AI technology. Targeting a broad customer base—including large employers, academic institutions, health plans, and direct consumers—Syrenity taps into national and global markets. This product diversifies revenue streams and bolsters the Company's standing in the growing mental health tech sector, driving sustainable growth.

  • Several government projects across multiple states are advancing into active implementation within high-margin business units. Launched the implementation of a four-year, $5.8 million training contract for healthcare professionals throughout Indiana, with revenue expected to start in 4Q24.

  • Secured healthcare workforce contracts across several states, including Delaware, Florida, and Kansas adding revenues to our legacy service line.

  • Completed a capital raise, generating gross proceeds of $2.1 million to bolster our financial flexibility and further support growth initiatives, including the product roadmap and the development of Syra's ethical, explainable, and responsible AI solutions in healthcare.

Management Commentary

Dr. Deepika Vuppalanchi, CEO of Syra Health, said, "We are excited to report year-over-year growth of 42%. Our commitment to increasing revenue and improving profit margins is driven by our strong team and a track record of success stories. We are laser-focused on expanding our portfolio of high-revenue clients in high-margin business units by delivering compelling value propositions tailored to meet their specific needs. Looking ahead, we anticipate that our mental health product, Syrenity, will attract new customers in the robust national and global mental and behavioral health markets, further diversifying our revenue streams.

Additionally, our extensive cost-saving strategy has yielded significant reductions in expenses across the board with a 69% decrease in net loss quarter-over-quarter. With our strong revenue growth, a robust sales pipeline spanning both public and private sectors, effective cost optimization strategies, and a steadfast commitment to innovative solutions, we are confident in our growth trajectory. We are determined to achieve profitability in 2025 and capitalize on the exciting opportunities ahead."

Q3 2024 Financial Results

Revenue for the quarter ended September 30, 2024, was $2.3 million, compared to the $1.6 million reported in the third quarter of 2023. Strong growth was driven by Population Health which grew 36% year over year, and Healthcare Workforce, which increased 54% year over year.

Gross profit margin was 30% in the third quarter of 2024, compared to 35% the previous year, attributed to revenue recognition in the third quarter of 2023 from our first milestone-based digital health product, Syrabot. With maintenance and operations for this project continuing for an additional three years, we believe we are well-positioned for future growth as we expand our digital health offerings and optimize our revenue streams.

Total operating expenses for the third quarter of 2024 were $1.1 million compared to $0.9 million in the third quarter of 2023, an increase of 22.2%.

Net loss for the third quarter of 2024 was $(417,535) compared to $(354,376) in the third quarter of 2023.

Total Revenue in the third quarter of 2024 was $2.3 million representing a 14.4% increase compared to the second quarter of 2024.

Gross profit margin in the third quarter of 2024 was 29.7%, compared to 17.8% in the second quarter of 2024. The 1190-basis point increase in gross margins quarter-over-quarter was primarily driven by cost-saving initiatives and enhanced operational efficiency, achieved by adopting a lean approach and reducing redundancies.

Total operating expenses in the third quarter of 2024 decreased 37% to $1.1 million compared to $1.74 million in the second quarter of 2024 due to a strategic focus on streamlining our operations and optimizing our workforce with a determination to reduce our cost structure.

Net loss for the third quarter of 2024 was $(417,535), a decrease of 69% from the net loss of $(1.4 million) in the second quarter of 2023. This improvement was due to restructuring efforts that reduced redundancies and increased operational efficiencies, providing a solid foundation to support ongoing business operations.

Cash on hand on September 30, 2024, was $2.7 million.

Conference Call

Management will hold a conference call to discuss the fiscal year's financial results at 9:00 am ET on October 29, 2024.

Interested parties can listen via a live webcast, from the link available in the Investor Relations section of the Company's website at https://ir.syrahealth.com/presentations/q3-2024-earnings-call.

A replay will be available after the call, in the Investor Relations section of the Company's website at https://ir.syrahealth.com/presentations/q3-2024-earnings-call.

ABOUT SYRA HEALTH

Syra Health leads the charge in addressing the toughest challenges in healthcare, from behavioral and mental health to population health, digital transformation, health education, and workforce development. Our technology-driven solutions focus on prevention, accessibility, and affordability, ensuring that every patient and provider gets the support they need. We proudly partner with payers, providers, life sciences organizations, academic institutions, and government entities to advance healthcare and improve outcomes. Learn more about our mission and services at www.syrahealth.com.

Forward-Looking Statements

Statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include but are not limited to, statements relating to the expected use of proceeds, the Company's operations and business strategy, and the Company's expected financial results. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained in this press release are based on management's current expectations and are subject to substantial risks, uncertainty, and changes in circumstances. Investors should read the risk factors set forth in our Form 10-K for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

SYRA HEALTH CORP.
CONDENSED BALANCE SHEETS



September 30,



December 31,




2024



2023




(Unaudited)





ASSETS









Current assets:









Cash


$

2,697,459



$

3,280,075


Accounts receivable, net



884,445




1,060,634


Accounts receivable related party



-




50,614











Other current assets



482,990




389,787


Total current assets



4,064,894




4,781,110











Property and equipment, net



34,625




78,974


Right-of-use asset



325,491




63,199











Total assets


$

4,425,010



$

4,923,283











LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)


















Current liabilities:









Accounts payable


$

212,931



$

462,991


Accrued expenses



309,606




198,978


Deferred revenue



6,108




-


Current portion of operating lease liability, related party



108,939




63,199


Notes payable



240,221




184,904


Total current liabilities



877,805




910,072











Non-current portion of operating lease liability, related party



216,552




-











Total liabilities



1,094,357




910,072











Commitments and contingencies


















Stockholders' equity (deficit):









Preferred stock, $0.001 par value, 10,000,000 shares authorized, no
shares designated, issued and outstanding



-




-


Class A common stock, $0.001 par value, 100,000,000 shares
authorized, 8,973,774 and 5,588,298 shares issued and outstanding
at September 30, 2024 and December 31, 2023, respectively



8,974




5,588


Convertible class B common stock, $0.001 par value, 5,000,000
shares authorized, 833,334 shares issued and outstanding



833




833











Additional paid-in capital



11,640,642




9,071,745


Accumulated deficit



(8,319,796)




(5,064,955)


Total stockholders' equity (deficit)



3,330,653




4,013,211











Total liabilities and stockholders' equity (deficit)


$

4,425,010



$

4,923,283


SYRA HEALTH CORP.
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)

















For the Three Months Ended



For the Nine Months Ended




2024



2023



2024



2023















Net revenues


$

2,253,336



$

1,581,344



$

5,975,357



$

3,748,943


Cost of services



1,585,038




1,026,803




4,777,765




2,919,087


Gross profit



668,298




554,541




1,197,592




829,856



















Operating expenses:

















Salaries and benefits



594,738




592,241




2,178,105




1,612,605


Professional services



153,803




58,875




489,839




424,379


Research and development expenses



34,821




-




590,263




-


Selling, general and administrative expenses



288,305




234,084




1,147,142




657,904


Depreciation



25,541




12,357




55,460




36,413


Total operating expenses



1,097,208




897,557




4,460,809




2,731,301



















Operating loss



(428,910)




(343,016)




(3,263,217)




(1,901,445)



















Other income (expense):

















Interest income



13,641




2,820




18,448




2,826


Interest expense



(2,266)




(14,180)




(10,072)




(44,449)


Total other income (expense)



11,375




(11,360)




8,376




(41,623)



















Net loss


$

(417,535)



$

(354,376)



$

(3,254,841)



$

(1,943,068)



















Weighted average common shares
outstanding - basic and diluted



7,264,768




4,360,426




6,789,209




4,380,267


Net loss per common share - basic and
diluted


$

(0.06)



$

(0.08)



$

(0.48)



$

(0.44)


SYRA HEALTH CORP.
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)




2024



2023


CASH FLOWS FROM OPERATING ACTIVITIES









Net loss


$

(3,254,841)



$

(1,943,068)


Adjustments to reconcile net loss to net cash used in operating
activities:









Depreciation



55,460




36,413


Bad debt expense



-




9,922


Common stock issued for services



74,647




-


Non-cash lease expense



63,199




90,162


Stock-based compensation, stock options



28,486




3,669


Changes in operating assets and liabilities:









Accounts receivable



176,189




136,324


Accounts receivable, related party



50,614




-


Other current assets



285,456




58,979


Accounts payable



(250,060)




500,391


Accounts payable, related parties



-




18,221


Deferred revenue



6,108




141,644


Accrued expenses



110,628




35,479


Operating lease liability



(63,199)




(90,162)


Net cash used in operating activities



(2,717,313)




(1,002,026)











CASH FLOWS FROM INVESTING ACTIVITIES









Purchase of property and equipment



(11,111)




(15,251)


Net cash used in investing activities



(11,111)




(15,251)











CASH FLOWS FROM FINANCING ACTIVITIES









Proceeds from sale of common stock and exercise of warrants



2,469,150




-


Payment of deferred offering costs



-




(589,059)


Proceeds received from line of credit



-




300,000


Repayments on line of credit



-




(750,397)


Proceeds received from advances, related party



-




1,295,010


Repayments on advances, related party



-




(678,611)


Repayments on notes payable



(323,342)




-


Proceeds received from convertible notes payable



-




1,455,000


Net cash provided by financing activities



2,145,808




1,031,943











NET CHANGE IN CASH AND CASH EQUIVALENTS



(582,616)




14,666


CASH AND CASH EQUIVALENTS AT BEGINNING OF
PERIOD



3,280,075




3,344


CASH AND CASH EQUIVALENTS AT END OF PERIOD


$

2,697,459



$

18,010











SUPPLEMENTAL INFORMATION:









Interest paid


$

10,072



$

28,533


Income taxes paid


$

-



$

-











NON-CASH INVESTING AND FINANCING ACTIVITIES:









Initial recognition of right-of-use asset and lease liability


$

325,491



$

-


Prepaid asset financed with note payable


$

378,659



$

-


Contacts:

For Investor or Media Inquiries:
Priya Prasad
COO & CFO
Syra Health Corp.
463-345-8963
priyap@syrahealth.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/syra-health-delivers-third-quarter-2024-financial-results-302289581.html

SOURCE Syra Health

Tags:


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today